After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring Novo Nordisk struck a licensing deal with a Swedish company worth over $1 billion. Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. The deal announced on Thursday give Novo a global exclusive license to a drug-delivery technology platform from Sweden’s Nanexa for certain therapeutic peptide drugs in medical conditions including obesity, type 2 diabetes and other cardiometabolic diseases.

Copyright ©2026 MarketWatch, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8 Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage.

Follow Steve on Twitter: @MKTWgoldstein. Here’s how to position your portfolio for the next AI wave, according to Morgan Stanley Why investors aren’t buying yet another attempt by the Treasury to calm the rattled bond market My friend grosses $300,000 a year with her pet-sitting business. She pays herself $50,000.

Should I do the same? 3 things Micron investors need to watch as the stakes get higher Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time.

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.